Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

Caitlin E. Cox

November 30, 2017

Presentation TCT 2017

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

Outcomes after TAVR in Bicuspid vs Tricuspid Aortic Valves: Results From a Multicenter Study with Propensity Matching

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

Flash Debate: Valve Thrombosis After TAVR Is a Serious Concern That Deserves Detection and Management!

Presenter: Gilles Dreyfus, Sanjay Kaul, Raj Makkar

November 01, 2017

Presentation TCT 2017

Topic 1: Anticoagulation After TAVR Should Now be Standard of Care PRO!

Presenter: Adrian P. Banning, Ted Feldman, Raj Makkar

November 01, 2017

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Shelley Wood

September 27, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Presentation TVT 2017

Subclinical Leaflet Thrombosis in Surgical and Transcatheter Bioprosthetic Aortic Valves Cautionary Findings and Clinical Implications

Presenter: Martin B. Leon, Hendrik Treede, Raj Makkar

June 16, 2017

Presentation TVT 2017

Management of Acute Coronary Syndromes and Left Main CAD in AS Patients: Case Examples and Procedural Techniques

Presenter: Raj Makkar

June 16, 2017

Presentation TVT 2017

The Portico TAVR System: A Cool Case, New Technology, and Clinical Program Updates

Presenter: Martin B. Leon, Michael J. Reardon, Raj Makkar

June 16, 2017

Presentation TVT 2017

A Critical Appraisal of REPRISE III

Presenter: Axel Linke, Jeffrey J. Popma, Raj Makkar

June 15, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

Advertisement

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Outcomes after TAVR in Bicuspid vs Tricuspid Aortic Valves: Results From a Multicenter Study with Propensity Matching

Flash Debate: Valve Thrombosis After TAVR Is a Serious Concern That Deserves Detection and Management!

Topic 1: Anticoagulation After TAVR Should Now be Standard of Care PRO!

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Subclinical Leaflet Thrombosis in Surgical and Transcatheter Bioprosthetic Aortic Valves Cautionary Findings and Clinical Implications

Management of Acute Coronary Syndromes and Left Main CAD in AS Patients: Case Examples and Procedural Techniques

The Portico TAVR System: A Cool Case, New Technology, and Clinical Program Updates

A Critical Appraisal of REPRISE III

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content